Results from a large, international, randomised, controlled trial have shown that there is a strong link between diabetics who have an abnormal heart rhythm (atrial fibrillation) and an increased risk of other heart-related problems and death. The findings are published in Europe's leading cardiology journal, the
European Heart Journal [1] today (Thursday 12 March).
The ADVANCE [2] study of 11,140 patients with type 2 diabetes found that patients who had atrial fibrillation (AF) at the start of the trial had a 61% increased risk of dying from any cause, a 77% increased risk of dying from cardiovascular causes such as a heart attack or stroke, and a 68% increased risk of developing heart failure or other cerebrovascular problems such as stroke, when compared with diabetic patients who did not have AF.
However, the study also found that if clinicians gave more aggressive treatments to the diabetic AF patients – in this study they treated them with a combination blood pressure lowering drugs, (perindopril and indapamide) – the risk of dying or developing any of these complications was reduced. It was also reduced in diabetic patients without AF who were given the same treatment.
Professor Anushka Patel, Director of the Cardiovascular Division at The George Institute for International Health (University of Sydney, Australia) and an Associate Professor in the Faculty of Medicine at the university, who led the study, said: "Active treatment produced similar relative benefits to patients with and without AF. However, because of their higher risk at the start of the study, the absolute benefit associated with active treatment was greater in patients with AF than without. We estimate that five years of active treatment would prevent one death among every 42 patients with AF and one death among every 120 patients without AF."